Replies to post #9979 on ANI Pharmaceuticals (ANIP)

[LordDarley]

I know very little about ADRO except for BioSante (now ANIP) having royalty rights for the GVAX Cancer Immunotherapy portfolio it sold to ADRO in 2013.

My knowledge is based on the excellent article JTFM wrote on seeking Alpha in 2015. For those who haven't read it, here is the link.
https://seekingalpha.com/article/2911376-why-ani-pharmaceuticals-should-outperform-short-term-and-long-term

Since then, it looks like a deal with JNJ has ended, and ADRO has laid off 59% of its workforce. Stock has cratered and some analyst thinks there's value at current price.

I'm curious what this means to ANIP? is it the royalty rights for the GVAX portfolio or is there something else? Is there something of real value?